Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eticyclidine SCHEMBL66697 | 0.90 | GRIN2D (0.57) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL10669385 | 0.88 | GRIN2D (0.58) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL5673123 | 0.87 | OPRM1 (0.50) | OPRM1OPRL1GRIN2DGRIN3BGRIA1 | |
| SCHEMBL19104839 | 0.86 | OPRM1 (0.41) | OPRM1OPRL1OPRK1GRIN2DGRIN3B | |
| SCHEMBL19093712 | 0.85 | MEN1 (0.52) | OPRM1OPRL1GRIN2DGRIN3BGRIA1 | |
| Hydrochloric Acid SCHEMBL19094252 | 0.85 | OPRM1 (0.40) | OPRM1OPRL1OPRK1GRIN2DGRIN3B | |
| Eticyclidine SCHEMBL7258514 | 0.84 | GRIN2D (0.51) | OPRM1OPRL1GRIN2DGRIN3BGRIA1 | |
| SCHEMBL22222298 | 0.83 | GRIN2D (0.50) | OPRM1OPRL1OPRK1GRIN2DGRIN3B | |
| SCHEMBL7306255 | 0.81 | OPRL1 (0.58) | OPRM1OPRL1POLB | |
| Eticyclidine SCHEMBL8452334 | 0.81 | GRIN2D (0.49) | OPRM1OPRL1GRIN2DGRIN3BGRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | OPRM1 40/4885OPRL1 13/4885OPRK1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.